These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 31560113)

  • 1. Ophthalmic Outcome in a Belgian Cohort of Cystinosis Patients Treated with a Compounded Preparation of Cysteamine Eye Drops: Retrospective Analysis.
    Peeters F; Cassiman C; Van Keer K; Levtchenko E; Veys K; Casteels I
    Ophthalmol Ther; 2019 Dec; 8(4):623-633. PubMed ID: 31560113
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Ocular Status of Cystinosis Patients Receiving a Hospital Pharmacy-Made Preparation of Cysteamine Eye Drops: A Case Series.
    Biswas S; Sornalingam K
    Ophthalmol Ther; 2019 Mar; 8(1):125-136. PubMed ID: 30519924
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A New Viscous Cysteamine Eye Drops Treatment for Ophthalmic Cystinosis: An Open-Label Randomized Comparative Phase III Pivotal Study.
    Liang H; Labbé A; Le Mouhaër J; Plisson C; Baudouin C
    Invest Ophthalmol Vis Sci; 2017 Apr; 58(4):2275-2283. PubMed ID: 28426870
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of topical cysteamine in nephropathic cystinosis.
    Al-Hemidan A; Shoughy SS; Kozak I; Tabbara KF
    Br J Ophthalmol; 2017 Sep; 101(9):1234-1237. PubMed ID: 28057644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Ocular treatment of cystinosis with eye drop containing cysteamine].
    Csorba A; Maka E; Szabó A; Kelen K; Reusz G; Nagy ZZ
    Orv Hetil; 2022 May; 163(21):846-852. PubMed ID: 35598215
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Storage Conditions on Stability of Ophthalmological Compounded Cysteamine Eye Drops.
    Reda A; Van Schepdael A; Adams E; Paul P; Devolder D; Elmonem MA; Veys K; Casteels I; van den Heuvel L; Levtchenko E
    JIMD Rep; 2018; 42():47-51. PubMed ID: 29214524
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A new gel formulation of topical cysteamine for the treatment of corneal cystine crystals in cystinosis: the Cystadrops OCT-1 study.
    Labbé A; Baudouin C; Deschênes G; Loirat C; Charbit M; Guest G; Niaudet P
    Mol Genet Metab; 2014 Mar; 111(3):314-320. PubMed ID: 24440466
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic Cysteamine Delivery Nanowafer as an Efficacious Treatment Modality for Corneal Cystinosis.
    Marcano DC; Shin CS; Lee B; Isenhart LC; Liu X; Li F; Jester JV; Pflugfelder SC; Simpson J; Acharya G
    Mol Pharm; 2016 Oct; 13(10):3468-3477. PubMed ID: 27571217
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized clinical trial of topical cysteamine disulfide (cystamine) versus free thiol (cysteamine) in the treatment of corneal cystine crystals in cystinosis.
    Iwata F; Kuehl EM; Reed GF; McCain LM; Gahl WA; Kaiser-Kupfer MI
    Mol Genet Metab; 1998 Aug; 64(4):237-42. PubMed ID: 9758713
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Limitations and Challenges in the Stability of Cysteamine Eye Drop Compounded Formulations.
    Martín-Sabroso C; Alonso-González M; Fernández-Carballido A; Aparicio-Blanco J; Córdoba-Díaz D; Navarro-García F; Córdoba-Díaz M; Torres-Suárez AI
    Pharmaceuticals (Basel); 2021 Dec; 15(1):. PubMed ID: 35056058
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Ozdemir HB; Özmen MC; Aktas Z; Hasanreisoglu M
    Indian J Ophthalmol; 2019 Jan; 67(1):153-155. PubMed ID: 30574930
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful use of topical cysteamine formulated from the oral preparation in a child with keratopathy secondary to cystinosis.
    Khan AO; Latimer B
    Am J Ophthalmol; 2004 Oct; 138(4):674-5. PubMed ID: 15488810
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of long-term cysteamine treatment in patients with cystinosis.
    Ariceta G; Giordano V; Santos F
    Pediatr Nephrol; 2019 Apr; 34(4):571-578. PubMed ID: 29260317
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gel formulations for treatment of the ophthalmic complications in cystinosis.
    Buchan B; Kay G; Heneghan A; Matthews KH; Cairns D
    Int J Pharm; 2010 Jun; 392(1-2):192-7. PubMed ID: 20382212
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Comparative Pharmacokinetic Study for Cysteamine-Containing Eye Drops as an Orphan Topical Therapy in Cystinosis.
    Csorba A; Katona G; Budai-Szűcs M; Balogh-Weiser D; Molnár P; Maka E; Kazsoki A; Vajna M; Zelkó R; Nagy ZZ; Balogh GT
    Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338900
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Feasibility of corneal drug delivery of cysteamine using vitamin E modified silicone hydrogel contact lenses.
    Hsu KH; Fentzke RC; Chauhan A
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):531-40. PubMed ID: 23665502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized placebo-controlled trial of cysteamine eye drops in nephropathic cystinosis.
    Kaiser-Kupfer MI; Gazzo MA; Datiles MB; Caruso RC; Kuehl EM; Gahl WA
    Arch Ophthalmol; 1990 May; 108(5):689-93. PubMed ID: 2185723
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Cysteamine eyedrops for treatment of corneal cysteine deposits in infantile cystinosis].
    Gräf M; Grote A; Wagner F
    Klin Monbl Augenheilkd; 1992 Jul; 201(1):48-50. PubMed ID: 1513127
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evolution of ocular manifestations in nephropathic cystinosis: a long-term study of a population treated with cysteamine.
    Dureau P; Broyer M; Dufier JL
    J Pediatr Ophthalmol Strabismus; 2003; 40(3):142-6. PubMed ID: 12795432
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Corneal crystals in nephropathic cystinosis: natural history and treatment with cysteamine eyedrops.
    Gahl WA; Kuehl EM; Iwata F; Lindblad A; Kaiser-Kupfer MI
    Mol Genet Metab; 2000; 71(1-2):100-20. PubMed ID: 11001803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.